Distributor inventory | Tablet
Vildagliptin 50 mg + Metformin 500 mg (as Metformin HCl)
Type 2 diabetes mellitus: to improve glycaemic control in adults when diet and exercise alone or current therapy is inadequate.
Vildagliptin is a DPP-4 inhibitor that increases incretin hormones (GLP-1, GIP), leading to increased glucose-dependent insulin release and reduced glucagon. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption and improves insulin sensitivity.
Oral tablet. Typically taken with meals to reduce stomach upset; swallow whole with water. Dose and frequency as prescribed by the doctor; do not stop or change dose without medical advice.
Common side effects of VILDAN M TAB may include:
Use only in type 2 diabetes (not for type 1 diabetes or diabetic ketoacidosis). Risk of lactic acidosis with metformin—higher in severe kidney disease, dehydration, sepsis, heavy alcohol use, or hypoxia; assess renal function before and during therapy. Use caution in liver disease; vildagliptin may raise liver enzymes—monitor if symptoms of hepatitis occur. Temporarily stop metformin before/at time of iodinated contrast studies or major surgery as advised. Monitor for pancreatitis symptoms (severe abdominal pain), and for hypoglycaemia if used with insulin or sulfonylureas.
